MABPHARM-B2181.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, MABPHARM-B (2181.HK) trades at a P/E of 21.30x, P/B of 9.20x, P/S of 2.35x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 14th percentile over 3Y); P/B sits at the 69th percentile over the trailing 10Y window (vs. 29th percentile over 3Y); P/S sits at the 6th percentile over the trailing 10Y window (vs. 10th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 74th percentile within its industry and the 75th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 54.9 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. MABPHARM-B operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2181 · SEHK: 2181 · 2181
Want the full picture on whether MABPHARM-B (2181.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 21.30 | ||||||
| P/B (MRQ) | 9.20 | ||||||
| P/S (TTM) | 2.35 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |